The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interstitial lung abnormalities in treatment-naive advanced NSCLC patients (pts): Prevalence and impact on survival.
Mizuki Nishino
No relevant relationships to disclose
Stephanie Cardarella
No relevant relationships to disclose
Suzanne Eleanor Dahlberg
No relevant relationships to disclose
Tetsuro Araki
No relevant relationships to disclose
Christine A. Lydon
No relevant relationships to disclose
Michael S. Rabin
No relevant relationships to disclose
Hiroto Hatabu
No relevant relationships to disclose
Bruce E. Johnson
Consultant or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; GE Healthcare; Genentech; Novartis; Pfizer; Transgenomic
Stock Ownership - KEW Group
Other Remuneration - Postmarketing royalties for EGFR mutation testing from Dana-Farber Cancer Institute